Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC
Open Access
Abstract
Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor, designed for the therapy of HER2-positive breast cancers. Inhibition of the epidermal growth factor receptor (EGFR, HER family) efficiently and selectively suppresses the proliferation of human TSC2-deficient smooth muscle cells and reverses lung changes in LAM/TSC. Our pilot study indicated that pyrotinib dramatically restrained the vitality of TSC2-deficient cells compared to its limited impact on TSC2-expression cells. Pyrotinib induced G1-phase arrest and triggered apoptosis by blocking abnormally activated CD24 in TSC2-deficient cells. CD24 is not only an important immune checkpoint, but is also involved in the regulation of signaling pathways. Pyrotinib inhibited the nuclear import of pEGFR and restrained the pEGFR/pSTAT3 signals, which directly boosted the transcriptional expression of CD24 by binding to its promoter region. In reverse, CD24 enhanced pEGFR function by directly binding. Pyrotinib specifically targeted TSC2-deficient cells, inhibited tumor cell viability and induced apoptosis through EGFR-STAT3/CD24 Loop in vivo and in vitro. Thus, pyrotinib may be a promising new therapeutic drug for TSC treatment.Keywords
Funding Information
- Nankai University (ZB19100128)
- Natural Science Foundation of Tianjin Municipality (18JCYBJC40700)
- State Key Laboratory of Pharmaceutical Biotechnology, Nan-jing University (KF-GN-201701)
- State Key Laboratory of Medicinal Chemical Biology (NanKai University) (2019014)
- LAM China Non-profit Organization Special Fund for LAM of Zhejiang Women and Children’s Foundation (LAM001-202205)
- Chongqing Science and Technology Bureau of China (cstc2019jcyj-msxm1819)
- National Natural Science Foundation of China (81901427)
This publication has 40 references indexed in Scilit:
- Targeting the ERBB family in cancer: couples therapyNature Reviews Cancer, 2013
- Development of a Lymphangioleiomyomatosis Model by Endonasal Administration of Human TSC2−/− Smooth Muscle Cells in MiceThe American Journal of Pathology, 2012
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialThe Lancet Oncology, 2012
- Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis ComplexHuman Mutation, 2011
- The tuberous sclerosis complexAnnals of the New York Academy of Sciences, 2010
- Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer CellsClinical Cancer Research, 2009
- Anti-EGFR Antibody Efficiently and Specifically Inhibits Human TSC2−/− Smooth Muscle Cell Proliferation. Possible Treatment Options for TSC and LAMPLOS ONE, 2008
- EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalizationBreast Cancer Research and Treatment, 2005
- TSC2 Mediates Cellular Energy Response to Control Cell Growth and SurvivalCell, 2003
- Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple OrgansThe American Journal of Human Genetics, 2001